Black Diamond Therapeutics : November 2023 Corporate Presentation

Black Diamond Therapeutics, Inc.

Developing MasterKey Therapies to Defeat Cancer Resistance

November 2023

Forward-Looking Statements

This presentation contains forward-looking statements of Black Diamond Therapeutics, Inc. ("we," "us," "our") within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "potential," "continue," "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective product candidates, the timing and advancement of current and planned clinical trials, our ability to replicate results achieved in our preclinical studies or clinical trials; research and development costs; the competitive landscape and market for our product candidates; and the timing and success of our development and commercialization of our product candidates, including our ability to establish and maintain collaborations or strategic relationships. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward- looking statements, see the section entitled "Risk Factors" in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), as well as discussions of potential risks, uncertainties, and other important factors in our other subsequent filings with the SEC. In addition, we have not conducted any head-to-head studies comparing our product candidates to any third-party drug products or candidates, whether investigated or approved. Information regarding other drug products in this presentation is meant to provide context for illustrative purposes only. Because there are no head-to-head studies, no conclusions should be made based on cross-study comparisons. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact.

2

Cancer is a Complex and Ever-Evolving Disease

Current targeted therapies were designed against a

limited subset of oncogenic mutations

Increasing adoption of liquid biopsies reveals a broader

set of oncogenic mutations

We are Developing MasterKey Therapies to Defeat Cancer Resistance

Our oral therapies are designed so that patients

have the opportunity for a longer, healthier, active life

Black Diamond's MasterKey

approach provides one solution for many mutations and addresses larger patient populations

3

Black Diamond Therapeutics At-a-Glance

Clinical-stage company		Experienced team with		Pipeline of oral, brain
advancing MasterKey		deep understanding		penetrant drug
therapies that expand		of cancer biology and		candidates selectively
the addressable patient		oncology drug		targeting families of
population		development		oncogenic mutations

Lead asset BDTX-1535		Multiple clinical		Strong balance sheet,
shows durable clinical		catalysts across the		with runway into 1H25;
responses in NSCLC,		pipeline in 2024		ended Q3 2023 with
with additional				$144.3M in cash
opportunity in GBM

4

MasterKey: One Solution for Many Mutations

Current Approach:	Black Diamond Approach:
Targeting single mutations in individual tumor types	Targeting families of oncogenic mutations

Limited addressable patient population

Expanded addressable patient population

Potent against broad mutation

families (including drug resistance mutations)

Brain penetrant to treat CNS disease

Selective targeting to deliver

well-tolerated therapies

5

Advancing Wholly-Owned Pipeline Across Multiple Oncology Indications

	Drug
Target	Candidate	Indication	Discovery	IND-Enabling	Phase 1	Phase 2/3
		EGFR-driven
		Dose expansion cohorts enrolling with data expected 2024
		NSCLC
EGFR	BDTX-1535	EGFR-driven
Dose escalation enrolled with data expected 2023;
		GBM	Window of Opportunity enrolling with data expected 2Q24

		KRAS-driven
		NSCLC
RAF	BDTX-4933	Other RAS/RAF-
		driven solid
		tumors

Phase 1 trial enrolling with dose escalation data expected 2024

6

BDTX-1535: EGFR MasterKey Inhibitor with Clinical Proof-of-Concept

MasterKey

Spares

WT-EGFR

BDTX-1535

Covalent

Brain

Penetrant

Clinical

PoC

Targets EGFR classical drivers, non-classical drivers, and resistance mutations

Selective for mutations versus WT-EGFR to deliver favorable safety profile

Oral small molecule with covalent MOA for potency and durability

Designed to treat CNS tumors and brain metastases

Clinical proof-of-concept in NSCLC achieved

WT=Wild-Type; MOA=mechanism of action; CNS=Central Nervous System; NSCLC=Non-Small Cell Lung Cancer	7

BDTX-1535: Phase 1 Clinical Proof-of-Concept Achieved in NSCLC

EGFR Mutant Non-Small	EGFR Altered
Cell Lung Cancer (NSCLC)	Glioblastoma (GBM)

Clinical proof-of-concept	Phase 1 update expected
achieved	later in 2023

8

BDTX-1535:

Summary of NSCLC Data

9

BDTX-1535 Addresses the Most Clinically Relevant EGFR Mutations in NSCLC: Classical / Non-Classical Drivers and C797S Resistance

Evolution of the EGFR mutation landscape over the past 20 years

2005	2013	2015	2018	2023	BDTX-1535

Classical drivers

					L858R / Ex19del	Non-classical drivers
						C797S resistance
Mutation	Classical EGFR
landscape		mutations
	described

T790M resistance

Treatments			T790M C797S
(2/3L)	(1L)	(2L)	(1L)
Sequencing
	Mutation specific sequencing	NGS revolution	Realization of >50 non-classical driver mutations
practices

BDTX-1535: opportunity to address all relevant mutations-critical for a 4th generation EFGR TKI

10